Abstract
Mutations in the c-KIT receptor occur somatically in many sporadic Gastrointestinal Stromal Tumors (GIST), and similar mutations have been identified at the germline level in kindreds with multiple GISTs. These mutations activate the tyrosine kinase activity of c-KIT and induce constitutive signaling. To investigate the function of activated c-KIT in GIST, we established a human GIST cell line, GIST882, which expresses an activating KIT mutation (K642E) in the first part of the cytoplasmic split tyrosine kinase domain. Notably, the K642E substitution is encoded by a homozygous exon 13 missense mutation, and, therefore, GIST882 cells do not express native KIT. GIST882 c-KIT protein is constitutively tyrosine phosphorylated, but tyrosine phosphorylation was rapidly and completely abolished after incubating the cells with the selective tyrosine kinase inhibitor STI571. Furthermore, GIST882 cells evidenced decreased proliferation and the onset of apoptotic cell death after prolonged incubation with STI571. Similar results were obtained after administering STI571 to a primary GIST cell culture that expressed a c-KIT exon 11 juxtamembrane mutation (K558NP). These cell-culture-based studies support an important role for c-KIT signaling in GIST and suggest therapeutic potential for STI571 in patients afflicted by this chemoresistant tumor.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Badache A, Muja N, DeVries G . 1998 Oncogene 17: 795–800
Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker B, Lydon N . 1996 Cancer Res. 56: 100–104
Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon N, Gilliland DG, Druker B . 1997 Blood 90: 4947–4952
Chan JK . 1999 Adv. Anat. Pathol. 6: 19–40
DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF . 2000 Ann. Surg. 231: 51–58
De Saint Aubain Somerhausen N, Fletcher CDM . 1998 Sarcoma 2: 133–141
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon N . 1996 Nat. Med. 2: 561–566
Druker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J, Sawyers C . 1999 Blood 94: 368a
Edmonson J, Marks R, Buckner J, Mahoney M . 1999 Proc. Am. Soc. Clin. Oncol. 18: 541a
Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH, O'Leary TJ . 1998 Lab. Invest. 78: 1633–1636
Heinrich M, Griffith D, Drucker B, Wait C, Ott K, Zigler A . 2000 Blood 96: 925–932
Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y . 1998 Science 279: 577–580
Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD . 2001 New Engl. J. Med. 344: 1052–1056
Koopman G, Reutelingsperger CPM, Kuijten GAM, Keehnen RMJ, Pals ST, van Oers MHJ . 1994 Blood 84: 1415–1420
Krystal GW, Honsawek S, Litz J, Buchdunger . 2000 Clin. Cancer Res. 6: 3319–3326
Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M . 1999 Am. J. Pathol. 154: 53–60
Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R, Nassar A, Sobin LH, Miettinen M . 2000 Am. J. Pathol. 157: 1091–1095
Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CD, Fletcher JA . 2000 Am. J. Pathol. 156: 791–795
Miettinen M, Sarlomo-Rikala M, Lasota J . 1999 Hum. Pathol. 30: 1213–1220
Moskaluk CA, Tian Q, Marshall CR, Rumpel CA, Franquemont DW, Frierson HF . 1999 Oncogene 18: 1897–1902
Nishida T, Hirota S, Taniguchi M, Hashimoto K, Isozaki K, Nakamura H, Kanakura Y, Tanaka T, Takabayashi A, Matsuda H, Kitamura Y . 1998 Nat. Gen. 19: 323–324
Nishida T, Hirota S . 2000 Histol. Histopathol. 15: 1293–1301
Rasheed S, Nelson-Rees WA, Toth EM, Arnstein P, Gardner MB . 1974 Cancer 33: 1027–1033
Reynolds JE, Fletcher JA, Lytle CH, Nie L, Morton CC, Diehl SR . 1992 Hum. Genet. 90: 450–456
Rubin BP, Fletcher JA, Fletcher CDM . 2000 Int. J. Surg. Pathol. 8: 5–10
Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M . 1998 Mod. Pathol. 11: 728–734
Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, Matsuda H, Kitamura Y . 1999 Cancer Res. 59: 4297–4300
Tuveson DA, Carter RH, Soltoff SP, Fearon DT . 1993 Science 260: 986–989
Ueyama T, Guo KJ, Hashimoto H, Daimaru Y, Enjoji M . 1992 Cancer 69: 947–955
Wang W, Healy M, Sattler M, Verma S, Lin J, Maulik G, Stiles C, Griffin J, Johnson B, Salgia R . 2000 Oncogene 19: 3521–3528
Acknowledgements
We thank Elisabeth Buchdunger and David Parkinson of Novartis for the STI571 used in this study. DA Tuveson is a Physician Scientist Research Fellow and T Jacks is an associate investigator of HHMI.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tuveson, D., Willis, N., Jacks, T. et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20, 5054–5058 (2001). https://doi.org/10.1038/sj.onc.1204704
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204704
Keywords
This article is cited by
-
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers
Molecular Cancer (2023)
-
The microphthalmia-associated transcription factor is involved in gastrointestinal stromal tumor growth
Cancer Gene Therapy (2023)
-
TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors
Drugs (2023)
-
The NCI-MATCH trial: lessons for precision oncology
Nature Medicine (2023)
-
Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma
British Journal of Cancer (2022)